Global Antibiotic R&D Partnership (GARDP)

⏰ Don’t miss your chance to present at #ACC2026!

Submit your oral or poster abstract by 14 Nov 2025 (17:00 GMT). Make sure to follow the submission guidelines carefully.

Submit now 🔗 acc-conference.com#posters

🔴 Live TODAY!

Join our #REVIVE webinar with Adrian Egli (University of Zürich) & Javier Fernández Domínguez (Pragmatech AI Solutions) on how AI can help detect and predict antimicrobial resistance.

🗓️17:00–18:30 CET

👉 Join here: go.bsky.app/redirect?u=h...

#AMR #Antibiotics #AI #REVIVE

📢 Last chance to register!

How can #AI help detect and predict antimicrobial resistance?

Join our REVIVE webinar with Adrian Egli (University of Zürich) & Javier Fernández Domínguez (Pragmatech AI Solutions).

🗓️ 28 Oct 2025 | 17:00–18:30 CET | Online
👉 Register: bit.ly/4hqdyky

🗓️ 2 days to go!

Can #AI reshape how we detect and manage antimicrobial resistance?

Find out in our #REVIVE webinar on 28 Oct, 17:00 CET.

👉 Register: revive.gardp.org/webinars/

🌍 At the GESDA Summit 2025, GARDP brought together scientists, funders, and policy leaders to explore bold solutions to #AMR.

From AI-driven discovery research to access partnerships like cefiderocol, discussions made one thing clear: incremental change isn’t enough.

YouTube video by ECHO India WHO AMR|13th October 2025 | English

📊 The @who.int #GLASSReport 2025 shows rising resistance, especially among Gram-negative pathogens.

At the launch, Dr. Jennifer Cohn said the data shows progress and urgency. Stronger surveillance, smarter antibiotic use and R&D are key to stay ahead of #AMR.

🎥 www.youtube.com/watch?v=GqRC...

Do you have an idea for a topic of interest for the antimicrobial R&D community? Why not suggest it to the REVIVE team at revive@gardp.org?

@cmicomms.bsky.social

📢 Exciting news!

Selected articles from our Antimicrobial Viewpoints series will now be co-published in CMI Communications, @escmid.bsky.social's open-access journal.

This collaboration will expand the reach and amplify the impact of these articles within the antimicrobial R&D community.

This year’s BioJapan saw a significant increase in attendance, with more than a 20% rise compared to last year📈

We are deeply grateful to everyone who visited the GARDP booth, showing warm interest and asking thoughtful questions🙏

GARDP will continue to address the global health challenge of #AMR🌍

Thank you for attending #BioJapan 2025

It was a valuable opportunity to highlight the importance of international collaboration in the field of infectious diseases and the venue was filled with vibrant energy throughout✨

⏳ One month to go!

Submit your abstract for ACC 2026 and join researchers worldwide shaping the future of #AMR.

Topics can include child and maternal health, diagnostics, stewardship, innovation, AI and more.

Deadline: 14 Nov 2025, 17:00 GMT
🔗 acc-conference.com#posters

‘As new infections outpace new drugs, are we sleepwalking into a global health disaster?’ | Dr Manica Balasegaram Much of the political momentum around the antimicrobial resistance crisis has dissipated, but a new report shows the danger to our health has not

📑 Drug-resistant infections have reached a tipping point. Without urgent action, #AMR deaths could rise by 70% by 2050.

We need innovation and access to the right antibiotics. 🌍

🔗Read Dr Manica Balasegaram’s @theguardian.com piece: www.theguardian.com/global-devel...

🌍 At #WHS2025, GARDP’s Peter Beyer highlighted the impact of tech transfers in a #GSK session.

"Technology transfer isn’t just about moving a production line; it’s about sharing know-how, building local capabilities, and ensuring that life-saving antibiotics can be sustainably manufactured."

Sharp global rise in antibiotic-resistant infections in hospitals, WHO finds Experts describe findings as deeply concerning and predict 70% increase in related deaths by 2050

🚨 @who.int reports a sharp global rise in antibiotic-resistant infections in hospitals.

"Until now, the #AMR narrative has focused rightfully on the overuse of antibiotics, but this isn’t enough." - Manica Balasegaram

@iansample.bsky.social for @theguardian.com
www.theguardian.com/world/2025/o...

Winners will receive:

- A €5,000 award to support their work
- A storytelling bootcamp with global experts
- An all-expenses-paid trip to Italy for the award ceremony
- The opportunity to share their work and build collaborations at Penta’s biennial scientific event.

The BFA spotlights health champions working at the grassroots and amplify their impact.

Nominations for the 2025-26 edition are open until 31 October 2025, 17:00 CET.

Nominations are now open for the second edition of the Penta Brighter Future Award (BFA), a biennial international award that celebrates inspiring contributions to maternal and child health worldwide.

👉 Submit your nomination: penta-id.org/bfa

Your input is highly appreciated, and we are looking forward to developing new exciting and enlightening content soon – watch this space!

🔗https://revive.gardp.org/

We recently had the pleasure to discuss the progress of the #REVIVE programme and potential new activities in our second annual advisory meeting.

A big Thank You to our 2026 REVIVE programme Advisory Group members.

💡 He also praised Japan’ innovation:
"The government’s initiative on clinical decision support system (CDSS) to further optimize utilization of antimicrobials is a strong example of next-gen leadership."

When asked what GARDP expects from Japan in the fight against #AMR at the Nikkei-FT Infectious Disease Conference session, Rahul Dwivedi of #GARDP said:
“Japan’s leadership is vital—especially in enabling access. With
Shionogi and CHAI, we’re working to expand antibiotic access in 135 countries.”

Co-creating an innovative AI platform to advance global health research | Medicines for Malaria Venture Researchers from around the world collaborate with MMV and deepmirror to adapt machine-learning platform to accelerate drug discovery.

GARDP joined 40+ global scientists in Geneva to help shape Drug Design for Global Health (dd4gh) — an AI and machine-learning platform being co-created by MMV and deepmirror.

It aims to accelerate identification of promising drug compounds for global health research.

🔗 bit.ly/4h0I1pe

Landscape analysis of commercially available and pipeline in vitro diagnostics for bacterial priority pathogens This report maps the available and pipeline diagnostics to detect and identify WHO bacterial priority pathogens and to perform phenotypic antimicrobial susceptibility testing (AST) or genotypic testin...

@who.int’s latest report on bacterial diagnostics highlights persistent gaps in rapid, affordable tools — especially where the need is greatest.

GARDP’s Teri Roberts contributed as part of the WHO expert group.

🔗 Read more: www.who.int/publications...

Analysis of antibacterial agents in clinical and preclinical development: overview and analysis 2025 The World Health Organization’s (WHO) “2025 Antibacterial agents in clinical and preclinical development: an overview and analysis” report provides a comprehensive evaluation of the global antibacteri...

@who.int’s new report shows the antibacterial R&D pipeline is shrinking — just 90 candidates remain in development, with limited innovation against critical pathogens.

Strengthening both discovery and access is key to tackling AMR.

🔗Read the report: www.who.int/publications...

📝 Call for abstracts is open for #ACC2026!

Researchers are invited to share their work on #AMR for short talks or poster presentations.

💡 Themes: child & maternal health, stewardship & access, clinical research, AI in health & more.

⏳ Deadline: 14 Nov 2025, 17:00 GMT
🔗 acc-conference.com#posters

日本経済新聞 - ニュース・速報 最新情報 日本経済新聞の電子版。日経や日経ＢＰの提供する経済、企業、国際、政治、マーケット、情報・通信、社会など各分野のニュース。ビジネス、マネー、IT、スポーツ、住宅、キャリアなどの専門情報も満載。

📍 Live from Osaka!

At the Nikkei–FT Infectious Disease Conference 2025, GARDP's Rahul Dwivedi joined global health leaders to discuss the urgent need to strengthen R&D and funding for infectious diseases.

🗞️🔗Read the Nikkei article published last night covering it

nikkei.com/article/DGXZ...

Finally, #BioJapan2025 starts tomorrow!

📍October 8–10 | Pacifico Yokohama

This year, we’re exhibiting again at the Swiss Pavilion (C-60)✨

💡GARDP is tackling drug-resistant bacterial infections. Come visit us to explore new partnerships and collaboration opportunities!

#SwissInnovation #AMR

🤝 Our team met with Shionogi’s CEO Dr Teshirogi, and Vice Chairperson Ms Sawada, to reaffirm our shared commitment to addressing #AMR.

Since 2022, Shionogi Japan has been collaborating with GARDP to ensure access to its innovative antibiotic in 135 countries worldwide. 💊

GARDP Statement on the Global Action Plan on AMR update | GARDP In May 2026, the World Health Assembly will consider adoption of an updated World Health Organization (WHO) Global Action Plan on AMR (GAP). The initial action

The @who.int’s updated Global Action Plan on #AMR, due in 2026, represents a pivotal opportunity to reshape the response to AMR.

GARDP calls for focus on four key areas:

1️⃣ Access to antibiotics
2️⃣ Children & newborns
3️⃣ Public-private partnerships
4️⃣ Financing the AMR response

🔗 bit.ly/48NxgV8

💬 Dr Jennifer Cohn shared this insight during a session at Keio University in Japan with over 60 participants, including AMR experts, healthcare professionals and students on global AMR countermeasures.